Opinion
Video
Exploring Toxicities for Second Line Treatments in mCRC
Author(s):
The panel examines prevalent adverse events experienced by patients receiving second-line biomarker-directed therapy for metastatic colorectal cancer.
EP: 1.Overview of Molecular Testing and Barriers in mCRC
EP: 2.Clinical Considerations for 2L Treatment Sequencing in mCRC
EP: 3.Novel Combination Regimens for 2L mCRC: Insights from ASCO 202
Now Viewing
EP: 4.Exploring Toxicities for Second Line Treatments in mCRC
EP: 5.Existing Challenges for Patients Receiving 3L+ Therapies in mCRC
EP: 6.Factors Driving 3L Therapeutic Selection for mCRC
EP: 7.Exploring Data Outcomes From the SUNLIGHT Trial
EP: 8.Fruquintinib for mCRC: Data from the FRESCO & FRESCO-2 Studies
EP: 9.Examining the Evolving 3L Treatment Landscape for mCRC
EP: 10.Additional Key Takeaways of ASCO 2024 Data in mCR
EP: 11.Future Outlooks in the Treatment of Metastatic Colorectal Cancer
- Briefly discuss common AEs for patients treated with 2L biomarker-directed therapy for mCRC.
- What similarities and differences can be observed based on specific clinically actionable targets?
- What strategies have you explored to mitigate and manage those events?
- Dr Marshall: Based on the following data updates presented in mCRC, how does this impact the future treatment landscape in the second line setting?
Related Videos
Related Content
%20(2)%201-Recovered-Recovered.jpg?fit=crop&auto=format)
